References
- MansfieldASHeikkilaPSVaaraATvon SmittenKAVakkilaJMLeideniusMHSimultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerBMC Cancer2009923119604349
- MullerAJDuhadawayJBDonoverPSSutanto-WardEPrendergastGCInhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapyNat Med200511331231915711557
- LeeGKParkHJMacleodMChandlerPMunnDHMellorALTryptophan deprivation sensitizes activated T cells to apoptosis prior to cell divisionImmunology2002107445246012460190
- MunnDHShafizadehEAttwoodJTBondarevIPashineAMellorALInhibition of T cell proliferation by macrophage tryptophan catabolismJ Exp Med199918991363137210224276
- MellorALMunnDHTryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunol Today1999201046947310500295
- MellorALMunnDHIDO expression by dendritic cells: tolerance and tryptophan catabolismNat Rev Immunol200441076277415459668
- GrohmannUFallarinoFPuccettiPTolerance, DCs and tryptophan: much ado about IDOTrends Immunol200324524224812738417
- KatzJBMullerAJPrendergastGCIndoleamine 2,3-dioxygen-ase in T-cell tolerance and tumoral immune escapeImmunol Rev200822220622118364004
- SchröcksnadelKWirleitnerBWinklerCFuchsDMonitoring tryptophan metabolism in chronic immune activationClin Chim Acta20063641–2829016139256
- NakamuraTShimaTSaekiAExpression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancerCancer Sci200798687488117433037
- YuJDuWYanFMyeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancerJ Immunol201319073783379723440412
- BrandacherGPerathonerALadurnerRPrognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cellsClin Cancer Res20061241144115116489067
- OkamotoANikaidoTOchiaiKIndoleamine 2,3-dioxygen-ase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cellsClin Cancer Res200511166030603916115948
- InoKYoshidaNKajiyamaHIndoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBr J Cancer200695111555156117117179
- MoonYWHajjarJHwuPNaingATargeting the indoleamine 2,3-dioxygenase pathway in cancerJ Immunother Cancer2015315126674411
- International Agency for Research on Cancer [webpage on the Internet]Estimated Incidence, Mortality and Prevalence Worldwide in 2012 IARC2012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed April 18, 2018
- YuJSunJWangSEUpregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasisClin Dev Immunol201120112110
- CuriglianoGGoldhirschAThe triple-negative subtype: new ideas for the poorest prognosis breast cancerJ Natl Cancer Inst Monogr201120114310811022043054
- Penault-LlorcaFVialeGPathological and molecular diagnosis of triple-negative breast cancer: a clinical perspectiveAnn Oncol201223Suppl 6vi19vi2223012297
- JamdadeVSSethiNMundheNAKumarPLahkarMSinhaNTherapeutic targets of triple-negative breast cancer: a reviewBr J Pharmacol2015172174228423726040571
- JacquemierJBertucciFFinettiPHigh expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinomaInt J Cancer201213019610421328335
- ChenXChoDBYangPCDouble staining immunohistochemistryN Am J Med Sci20102524124522574297
- KimSParkSChoMSLimWMoonBISungSHStrong correlation of indoleamine 2,3-Dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancerJ Cancer20178112413028123606
- DillEADillonPMBullockTNMillsAMIDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1Mod Pathol201831101513152229802358
- SolimanHRawalBFulpJAnalysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistryCancer Immunol Immunother201362582983723344392
- WeiLZhuSLiMHigh indoleamine 2,3-Dioxygenase is correlated with microvessel density and worse prognosis in breast cancerFront Immunol2018972429719533
- HuangAFuchsDWidnerBGloverCHendersonDCAllen-MershTGSerum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancerBr J Cancer200286111691169612087451
- InoKYamamotoEShibataKInverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survivalClin Cancer Res20081482310231718413819
- AstigianoSMorandiBCostaREosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancerNeoplasia20057439039615967116
- WeinlichGMurrCRichardsenLWinklerCFuchsDDecreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patientsDermatology2007214181417191041
- TakaoMOkamotoANikaidoTIncreased synthesis of indole-amine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancerOncol Rep20071761333133917487387
- LevinaVSuYGorelikEImmunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formationClin Dev Immunol2012201212112
- NoonepalleSKGuFLeeEJPromoter methylation modulates indoleamine 2,3-dioxygenase 1 induction by activated T cells in human breast cancersCancer Immunol Res20175433034428264810
- ThéateIvan BarenNPilotteLExtensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissuesCancer Immunol Res20153216117225271151